A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase

Trial Profile

A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Agalsidase beta (Primary)
  • Indications Gaucher's disease type I
  • Focus Adverse reactions
  • Sponsors ISU Abxis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top